Copyright: ©Author(s) 2026.
World J Orthop. Nov 18, 2026; 17(11): 126620
Published online Nov 18, 2026. doi: 10.5312/wjo.126620
Published online Nov 18, 2026. doi: 10.5312/wjo.126620
Table 2 Dosing regimens of bypassing agents in people with hemophilia with inhibitors aged > 65 years
| Drug | Dosing for minor orthopedic surgery | Dosing for major orthopedic surgery | Comments |
| Recombinant factor VII activated | 90 µg/kg/dose immediately before surgery and every 2 hours for 2 days and then every 2-6 hours until healed | 90 µg/kg/dose immediately before surgery and every 2 hours for 2 days. Then every 2-3 hours for 5 days, then every 4 hours until days 7-10, then every 6 hours until days 14-21 | Preferred drug for individuals with hemophilia B and high-titer inhibitors per WFH guidelines since aPCCs contains factor IX and may cause or worsen an allergic reaction |
| For individuals with factor IX deficiency, low dose (15-30 µg/kg) in combination with tranexamic acid has been shown to be effective for major surgery in limited studies and can be considered for those at risk of thrombosis | |||
| aPCCs | 50-100 U/kg immediately prior to surgery and then every 6-12 hours | 50-100 U/kg immediately prior to surgery, then every 6-12 hours | Maximum: 100 units/kg/dose; 200 units/kg/day) |
| Less preferred for hemophilia B individuals with high-titer inhibitors per WFH guidelines |
- Citation: Rodriguez-Merchan EC, Ribbans WJ, De la Corte-Rodriguez H. Musculoskeletal problems of people with hemophilia aged > 65 years. World J Orthop 2026; 17(11): 126620
- URL: https://www.wjgnet.com/2218-5836/full/v17/i11/126620.htm
- DOI: https://dx.doi.org/10.5312/wjo.126620